Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

The employee awards cover 17,250 option shares and 8,626 restricted stock unit shares, with vesting subject to continued service.

Rhea-AI Summary

Edgewise Therapeutics (EWTX) granted inducement stock options and restricted stock units to two new non-executive employees on October 30, 2026.

The options cover 17,250 shares at an exercise price of $38.90 per share, equal to the grant-date closing price. Restricted stock units cover another 8,626 shares. Options vest 25% on each employee's first employment anniversary, then 1/48th monthly. Restricted stock units vest one-fourth annually on the first four grant-date anniversaries. Both awards require continued service and were granted under the 2024 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.17,250 stock options at $38.90 per share and 8,626 restricted stock units create potential shareholder dilution.

Key Figures

Option shares: 17,250 shares Restricted stock units: 8,626 shares New employees: 2 employees +4 more

Option shares

17,250 shares

Inducement stock options granted to 2 new non-executive employees

Restricted stock units

8,626 shares

Inducement RSU awards granted to 2 new non-executive employees

New employees

2 employees

Recipients of the inducement awards

Option exercise price

$38.90 per share

Equal to the closing price on the grant date

Initial option vesting

25%

Vests on the one-year anniversary of each employee's start date

Subsequent option vesting

1/48th monthly

Additional option shares vest monthly after the initial vesting date, subject to continued service

RSU vesting

1/4th annually

Vests on each of the first four grant-date anniversaries, subject to continued service

Key Terms

restricted stock units

1 terms

restricted stock units financial

"awards of inducement restricted stock units (each, an "RSU award")"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOULDER, Colo., Nov. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today announced that on October 30, 2026, Edgewise granted inducement stock options to purchase a total of 17,250 shares of Edgewise's common stock and awards of inducement restricted stock units (each, an "RSU award") covering a total of 8,626 shares of Edgewise's common stock to 2 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan"). 

Each inducement stock option has an exercise price of $38.90 per share, which is equal to the closing price of a share of Edgewise common stock on the grant date, and shall vest as follows: 25% of the shares subject to such inducement stock option shall vest on the one year anniversary of the start date of each employee, and an additional one forty-eighth (1/48th) of the shares subject to such inducement stock option shall vest monthly thereafter, subject to the employee's continued service.

Each inducement RSU award shall vest as follows: one-fourth (1/4th) of the shares subject to each inducement RSU award shall vest on the first, second, third and fourth yearly anniversaries of the grant date, subject to the employee's continued service.

Each inducement award is subject to the terms of the Inducement Plan and related forms of agreements, and were granted as inducements material to these employees to enter into employment with Edgewise in accordance with Nasdaq Listing Rule 5635(c)(4). 

About Edgewise Therapeutics 
Edgewise Therapeutics is a cardiovascular biotechnology company developing novel therapies intended to address cardiac equilibrium, the balance of contraction and relaxation across the cardiac cycle. Drawing on deep expertise in integrated muscle physiology and small molecule drug development, Edgewise is advancing novel therapies intended to fine-tune cardiac muscle function and improve treatment options for people with symptomatic hypertrophic cardiomyopathy and heart failure. To learn more, go to edgewisetx.com or follow Edgewise on LinkedIn, X, Facebook and Instagram.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-302925830.html

SOURCE Edgewise Therapeutics

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement equity awards did Edgewise Therapeutics grant on October 30, 2026?

Edgewise granted two new non-executive employees options to purchase 17,250 shares at $38.90 per share and restricted stock units covering 8,626 shares. The option exercise price equals the common stock's closing price on the grant date.

How do Edgewise Therapeutics' October 2026 inducement awards vest?

The options vest 25% on each employee's first employment anniversary, followed by 1/48th monthly thereafter. Restricted stock units vest one-fourth on each of the first four anniversaries of the grant date. Both schedules are subject to continued service.